• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    REPAY Appoints New Chief Financial Officer

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    $MRK
    Real Estate
    Real Estate
    Real Estate
    Real Estate
    Get the next $CNDT alert in real time by email

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025.

    "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO.

    Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT) ("Conduent"). He previously served as Conduent's Global Head of Strategy, Corporate Development and Advisor to CEO. Prior to Conduent, Rob spent seven years at Fiserv, Inc. (NYSE:FI) holding positions as Senior Vice President, General Manager, and CFO across several divisions. Prior to Fiserv, he was the Global Head of FP&A and Investor Relations at Integra Lifesciences, Inc. (NASDAQ:IART). He previously held various finance, accounting, and strategy roles at Firmenich, Inc, Bristol-Myers Squibb Co. (NYSE:NMY), and Merck & Co Inc. (NYSE:MRK). Rob began his career as an auditor for KPMG LLP, and he earned his MBA and bachelor's degree in accounting from Rider University.

    "With Rob's appointment, interim CFO Thomas Sullivan will return to his role as Chief Accounting Officer. We are extremely grateful for Thomas's help in managing the finance organization over the past several months and the entire REPAY team for supporting the company through the CFO transition," said John Morris.

    About REPAY

    REPAY provides integrated payment processing solutions to verticals that have specific transaction processing needs. REPAY's proprietary, integrated payment technology platform reduces the complexity of electronic payments for clients, while enhancing the overall experience for consumers and businesses.

    Forward-Looking Statements

    This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about REPAY's expectations with respect to the announced leadership changes. Such forward-looking statements are based upon the current beliefs and expectations of REPAY's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond REPAY's control, including, without limitation, the factors described in REPAY's reports filed with the U.S. Securities and Exchange Commission. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. All information set forth herein speaks only as of the date hereof in the case of information about REPAY or the date of such information in the case of information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250811411111/en/

    Investor Relations for REPAY:

    [email protected]



    Media Relations for REPAY:

    Kristen Hoyman

    [email protected]

    Get the next $CNDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNDT
    $FI
    $IART
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    2/25/2026$142.00Outperform
    RBC Capital Mkts
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    11/13/2025$105.00Sector Outperform
    Scotiabank
    Fiserv Inc.
    $FI
    11/5/2025$62.00Outperform → Neutral
    BNP Paribas Exane
    More analyst ratings

    $CNDT
    $FI
    $IART
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Agadi Harshavardhan V bought $182,909 worth of shares (117,099 units at $1.56) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/23/26 5:21:51 PM ET
    $CNDT
    Real Estate

    Chief Executive Officer Agadi Harshavardhan V bought $313,720 worth of shares (220,000 units at $1.43) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:36:25 AM ET
    $CNDT
    Real Estate

    Director Palau Hernandez Margarita bought $72,650 worth of shares (50,000 units at $1.45) (SEC Form 4)

    4 - CONDUENT Inc (0001677703) (Issuer)

    2/20/26 11:33:12 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    REPAY to Announce Fourth Quarter and Full Year 2025 Results on March 9, 2026

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today announced that the Company will host a conference call to discuss fourth quarter and full year 2025 financial results on Monday, March 9, 2026 at 5:00pm ET. A press release with fourth quarter and full year 2025 financial results will be issued after the market closes that same day. The conference call will be webcast live from the Company's investor relations website at https://investors.repay.com/ under the "Events" section. The conference call can also be accessed live over the phone by dialing (877) 407-3982, or for international callers (201) 493-6

    3/2/26 4:10:00 PM ET
    $RPAY
    Real Estate

    KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

    KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the final analy

    2/27/26 10:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Merck with a new price target

    RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00

    2/25/26 7:52:46 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Barnett Naomi covered exercise/tax liability with 5,305 shares, decreasing direct ownership by 3% to 173,366 units (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    2/23/26 6:57:49 PM ET
    $RPAY
    Real Estate

    Chief Accounting Officer Sullivan Thomas Eugene covered exercise/tax liability with 4,200 shares, decreasing direct ownership by 2% to 165,306 units (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    2/23/26 6:57:58 PM ET
    $RPAY
    Real Estate

    General Counsel Dempsey Tyler B covered exercise/tax liability with 7,710 shares, decreasing direct ownership by 2% to 327,694 units (SEC Form 4)

    4 - Repay Holdings Corp (0001720592) (Issuer)

    2/23/26 6:56:53 PM ET
    $RPAY
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    SEC Filings

    View All

    SEC Form S-3ASR filed by Integra LifeSciences Holdings Corporation

    S-3ASR - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    2/26/26 4:59:51 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Integra LifeSciences Holdings Corporation

    10-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    2/26/26 4:02:58 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    2/26/26 6:15:14 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $CNDT
    $FI
    $IART
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integra LifeSciences Announces Key Executive Leadership Appointments

    PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company. The company also announced the appointments of Michael Hutchinson as executive vice president, chief legal officer and secretary, and Kerri DiPietro as corporate vice president and chief quality officer. The creation of the chief technology officer (CTO) position underscores Integra's commitment to build

    2/17/26 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Conduent Appoints Harsha V. Agadi as Chief Executive Officer

    Succeeds Cliff Skelton, who will step down as President and CEO Margarita Paláu-Hernández appointed independent Chair of the Board Conduent Incorporated (NASDAQ:CNDT), a global technology-driven business solutions and services company, today announced that the Board of Directors has appointed Harsha V. Agadi, Chairman of Conduent's Board of Directors, as Chief Executive Officer, effective immediately. As part of this transition, Mr. Agadi will step down as Chairman of the Board, and Margarita Paláu-Hernández has been appointed independent Chair of the Board. Mr. Agadi succeeds Cliff Skelton, who will step down as President, Chief Executive Officer, and a member of the Board of Directors

    1/16/26 4:30:00 PM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Financials

    Live finance-specific insights

    View All

    REPAY to Announce Fourth Quarter and Full Year 2025 Results on March 9, 2026

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today announced that the Company will host a conference call to discuss fourth quarter and full year 2025 financial results on Monday, March 9, 2026 at 5:00pm ET. A press release with fourth quarter and full year 2025 financial results will be issued after the market closes that same day. The conference call will be webcast live from the Company's investor relations website at https://investors.repay.com/ under the "Events" section. The conference call can also be accessed live over the phone by dialing (877) 407-3982, or for international callers (201) 493-6

    3/2/26 4:10:00 PM ET
    $RPAY
    Real Estate

    Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

    PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) --  Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share were $0.83, compared to $0.97 in the fourth quarter of 2024. Full-Year 2025 Reported revenues were $1,635.2 million, representing an increase of 1.5% on a reported basis and

    2/26/26 6:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Conduent Reports Fourth Quarter and Full Year 2025 Financial Results

    Key Q4 and Full Year 2025 Highlights Revenue and Adj. Revenue(1): Q4 $770M / FY $3,042MPre-tax Income (Loss): Q4 $(28)M / FY $(160)MAdj. EBITDA Margin(1): Q4 6.5% / FY 5.4%New Business Signings ACV(2): Q4 $152M / FY $517M FLORHAM PARK, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Conduent Incorporated (NASDAQ:CNDT), a global technology driven business process solutions and services company, today announced its fourth quarter and full year 2025 financial results. Harsha V. Agadi, Chief Executive Officer stated. "Q4 and full‑year 2025 reflected mixed execution for Conduent. In our Government and Transportation segments, we saw improving revenue trends, continued growth in the sales pipeline, a

    2/12/26 8:00:00 AM ET
    $CNDT
    Real Estate

    $CNDT
    $FI
    $IART
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Repay Holdings Corporation

    SC 13G - Repay Holdings Corp (0001720592) (Subject)

    11/14/24 5:17:53 PM ET
    $RPAY
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Conduent Incorporated

    SC 13G/A - CONDUENT Inc (0001677703) (Subject)

    11/14/24 1:28:32 PM ET
    $CNDT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Fiserv Inc.

    SC 13G/A - FISERV INC (0000798354) (Subject)

    11/14/24 1:22:34 PM ET
    $FI
    Real Estate